Investigational drug · Phase 3
ALK-001
Also called: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Gildeuretinol acetate
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "ALK-001"
First trial start
2015
Aug 2015
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALK-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Approved drugs for the same conditions: Wet macular degeneration · Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALK-001" as an intervention, largest first.
- Study of ALK-001 on the Progression of Stargardt DiseasePivotal-lookingRecruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT07419334 · 230 participants (planned) · Start Jun 3, 2026 · Primary completion Oct 2029
Drug: ALK-001; Placebo · For: Stargardt Disease
Sites: Phoenix, Arizona; Aurora, Colorado; Gainesville, Florida · 14 sites in all
- Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)Active, not recruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT04239625 · 200 participants (planned) · Start Dec 20, 2019 · Primary completion Dec 2028
Drug: ALK-001 · For: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy and 1 more
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 8 sites in all
- Phase 2/3 Study of ALK-001 in Geographic AtrophyPivotal-lookingCompleted
Alkeus Pharmaceuticals, Inc.Industry
NCT03845582 · 200 participants · Start May 7, 2019 · Primary completion Jul 25, 2023
Drug: ALK-001 oral capsule; Placebo oral capsule · For: Geographic Atrophy; Age Related Macular Degeneration; AMD and 1 more
Sites: Phoenix, Arizona; Beverly Hills, California; Lakewood, Colorado · 24 sites in all
- Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseasePivotal-lookingActive, not recruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT02402660 · 160 participants (planned) · Start Aug 2015 · Primary completion Jun 30, 2028
Drug: ALK-001; Placebo · For: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy and 1 more
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 14 sites in all
Alkeus Pharmaceuticals, Inc.Industry
NCT02230228 · 40 participants · Start Apr 2014 · Primary completion Sep 2014
Drug: ALK-001 (No generic name) · For: Stargardt Disease; Age-related Macular Degeneration; Other Retinal Dystrophies
Newest research
PubMed records naming it or its code names, newest first.
- Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial.
Kay CN, Saad L, DeBartolomeo G, et al. · JAMA Ophthalmol 2026
- Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial.
Boyer DS, Saad L, Washington I, et al. · Ophthalmol Retina 2026
- Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease.
Barthelemy N, Lee W, Gregori NZ, et al. · Curr Opin Ophthalmol 2026
- Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape.
Dayma K, Rajanala K, Upadhyay A · Int J Mol Sci 2025
- Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease.
Wang L, Shah SM, Mangwani-Mordani S, et al. · J Clin Med 2023
- Clinical Application and Synthesis Methods of Deuterated Drugs.
Xu XL, Zhang W, Rao GW · Curr Med Chem 2023
Also in development for Stargardt Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.